Myeloid cell microsomal prostaglandin e synthase-1 fosters atherogenesis in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 18, 2014, Pages 6828-6833

  Chen, Lihong ^a   Yang, Guangrui ^a   Monslow, James ^b   Todd, Leslie ^b   Cormode, David P ^b   Tang, Jun ^c   Grant, Gregory R ^a   DeLong, Jonathan H ^b   Tang, Soon Yew ^a   Lawson, John A ^a   Pure, Ellen ^b   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Prostanoid

Indexed keywords

CHOLESTEROL; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LOW DENSITY LIPOPROTEIN RECEPTOR; PROSTAGLANDIN E SYNTHASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA INJURY; ARTERY LESION; ARTICLE; ATHEROGENESIS; BONE MARROW CELL; CELL INFILTRATION; CELLS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; EFFUSION; ENDOTHELIUM CELL; FEMALE; FOAM CELL; GENE DELETION; GENE INACTIVATION; GENOTYPE; HYPERLIPIDEMIA; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; PROSTANOID;

ANIMALS; ATHEROSCLEROSIS; CELL MOVEMENT; ENDOTHELIAL CELLS; FEMALE; HYPERLIPIDEMIAS; INTRAMOLECULAR OXIDOREDUCTASES; LIPID METABOLISM; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MICROSOMES; MYELOID CELLS; MYOCYTES, SMOOTH MUSCLE; OXIDATIVE STRESS; RECEPTORS, LDL;

EID: 84899863296     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1401797111     Document Type: Article

References (46)

1. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA (2009) Prostanoids in health and disease. J Lipid Res 50(Suppl):S423-S428.
2. Yu Y, et al. (2012) Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 4(132):32ra54.
3. Cannon CP, et al.; MEDAL Steering Committee (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet 368(9549):1771-1781.
4. Struthmann L, et al. (2009) Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo. J Thromb Haemost 7(10):1727-1735.
5. Samuelsson B, Morgenstern R, Jakobsson PJ (2007) Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol Rev 59(3):207-224.
6. Kudo I, Murakami M ( 2005) Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol 38(6):633-638.
7. WangM, Song WL, Cheng Y, Fitzgerald GA (2008)Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease. J Intern Med 263(5):500-505.
8. Chen L, et al. (2013) Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1. Circulation 127(2):233-243.
9. Wang M, et al. (2006) Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 103(39):14507-14512.
10. Wang M, et al. (2011) Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury. Circulation 123(6):631-639.
11. Wang M, et al. ( 2008) Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117(10):1302-1309.
12. Trebino CE, et al. (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 100(15):9044-9049.
13. Kamei D, et al. (2004) Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J Biol Chem 279(32):33684-33695.
14. Chen M, et al. (2008) Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serumtransfer arthritis. Arthritis Rheum 58(5):1354-1365.
15. Suzuki J, et al. (2011) Roles of prostaglandin E2 in cardiovascular diseases. Int Heart J 52(5):266-269.
16. Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: Structures, properties, and functions. Physiol Rev 79(4):1193-1226.
17. Yu Z, et al. (2012) Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc Natl Acad Sci USA 109(17):6727-6732.
18. Egan KM, et al. (2004) COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306(5703):1954-1957.
19. Kobayashi T, et al. (2004) Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114(6):784-794.
20. Fries S, Grosser T (2005) The cardiovascular pharmacology of COX-2 inhibition. Hematology (Am Soc Hematol Educ Program) 2005:445-451.
21. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I (1999) Conditional gene targeting in macrophages and granulocytes usi ng LysMcre mice. Transgenic Res 8(4): 265-277.
22. Hallemeesch MM, et al. (2003) NO production by cNOS and iNOS reflects blood pressure changes in LPS-challenged mice. Am J Physiol Endocrinol Metab 285(4): E871-E875.
23. Duivenvoorden R, et al. (2014) A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 5:3065.
24. Lawson JA et al. 1998 Identification of two major F2 isoprostanes, 8,12-iso-and 5-epi-8, 12-iso-isoprostane F2alpha-VI, in human urine J Biol Chem 273 45 29295-29301
25. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 116(1):4-15.
26. Rudic RD, et al. (2005) COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 96(12):1240-1247.
27. Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31(5):986-1000.
28. Claveau D, et al. (2003) Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygen ase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol 170(9):4738-4744.
29. Barbieri SS, et al. (2012) Cyclooxygenase-2-derived prostacyclin regulates arteri al thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner. Circulation 126(11):1373-1384.
30. Nagai N, Hoylaerts MF, Gallacher DJ, Lu HR, Lijnen HR (2008) Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. Thromb Res 122(5):668-673.
31. Murata T, et al. (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388(6643):678-682.
32. Cheng Y, et al. (2006) Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116(5):1391-1399.
33. Jia Z, Aoyagi T, Yang T (2 010) mPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP. Hypertension 55(2):539-546.
34. Jia Z, et al. (2008) Microsomal prostaglandin synthase-1-derived prostaglandin E2 protects against angiotensin II-induced hypertension via inhibition of oxidative stress. Hypertension 52(5):952-959.
35. Francois H, et al. (2007) Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol 18(5):1466-1475.
36. Facemire CS, Griffiths R, Audoly LP, Koller BH, Coffman TM (2010) The impact of microsomal prostaglandin e synthase 1 on blood pressure is determined by genetic background. Hypertension 55(2):531-538.
37. Degousee N, et al. (2008)Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left vent ricular remodeling after myocardial infarction. Circulation 117(13):1701-1710.
38. Zhang J, et al. (2013) Cyclooxygenase-2-derived prostaglandin E2 promotes injuryinduced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res 113(2):104-114.
39. Ghoshal S, Loftin CD (2012) Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice. PLoS ONE 7(11):e44369.
40. Lu Y, et al. (2011) Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate. Arthritis Res Ther 13(2):R56.
41. Ayala-López W, Xia W, Varghese B, Low PS (2010) Imaging of atherosclerosis in apoliprotein e knockout mice: Targeting of a folate-conjugated radiopharmaceutical to activated macrophages. J Nucl Med 51(5):768-774.
42. Cormode DP, et al. (2010) Atherosclerotic plaque composition: Analysis with multicolor CT and targeted gold nanoparticles. Radiology 256(3):774-782.
43. Sinha P, et al. (2004) Mouse lysozyme-Mknockout mice reveal how the self-determinant hierarchy shapes the T cell repertoire against this circulating self antigen in wild-type mice. J Immunol 173(3):1763-1771.
44. Hu Y (2012) Isolation of human and mouse neutrophils ex vivo and in vitro. Methods Mol Biol 844:101-113.
45. Inaba K et al. 2009 Isolation of dendritic cells Curr Protoc Immunol Chapter 3:Unit 3.7
46. Song WL, Lawson JA, Wang M, Zou H, FitzGerald G A (2007) Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: A detailed HPLC/MS/MS method. Methods Enzymol 433:51-72.